Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus Completes Merger with Indivior to Form Combined CNS Biopharmaceutical Company

Neutral Impact 5 of 5 m&a

Supernus Pharmaceuticals has completed its merger with Indivior Pharmaceuticals, forming a combined entity operating as Supernus, Inc. Under the terms of the agreement, Supernus stockholders received 1.5401 shares of Indivior common stock for each share owned, resulting in former Indivior stockholders owning approximately 56.5% and former Supernus stockholders owning approximately 43.5% of the combined company. The company also entered into a $650 million senior secured term loan facility to help fund a $1.0 billion special cash dividend to legacy Indivior stockholders.

Key points

  • The merger was completed on November 2, 2026, combining Supernus Pharmaceuticals and Indivior Pharmaceuticals into Supernus, Inc.
  • Supernus stockholders received 1.5401 shares of Indivior common stock for each share of Supernus common stock owned.
  • The combined company secured a $650 million term loan facility with Citibank, N.A. to help finance a $1.0 billion aggregate special cash dividend to legacy Indivior stockholders.
  • Former Indivior stockholders own approximately 56.5% and former Supernus stockholders own approximately 43.5% of the combined company on a fully diluted basis.

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECNov 2, 2026, 9:28 AM ET
Accession number0001104659-26-121014

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed2.03 New Direct Financial Obligation3.03 Change to Shareholder Rights5.01 Change in Control5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Google Gemini, gemini-3.5-flash-lite) on Nov 2, 2026, 11:17 AM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.